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1. INTRODUCTION {#mgg3411-sec-0005}
===============

Dystonia is defined as a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both (Albanese et al., [2013](#mgg3411-bib-0002){ref-type="ref"}). In general, adult‐ or late‐onset dystonia without evidence of overt degeneration or structural lesions of the nervous system is referred to as isolated dystonia and can be inherited in an autosomal‐dominant fashion with reduced penetrance. The most common forms of focal dystonia are cervical dystonia and blepharospasm (BSP). Blepharospasm (BSP) (OMIM: 606798) is characterized by involuntary orbicularis oculi spasms that are usually bilateral, synchronous, and symmetrical (Defazio et al., [2015](#mgg3411-bib-0015){ref-type="ref"}). Review of BSP epidemiological data provides prevalence estimates ranging from 16 to 133 per million (Defazio, Abbruzzese, Livrea, & Berardelli, [2004](#mgg3411-bib-0012){ref-type="ref"}). BSP is significantly more common in females (\>2F:1M) with a mean age of onset at approximately 55 years (O\'Riordan et al., [2004](#mgg3411-bib-0065){ref-type="ref"}). In comparison to cervical and laryngeal dystonia, BSP is more likely to spread to other body parts (Weiss et al., [2006](#mgg3411-bib-0094){ref-type="ref"}). Most commonly, BSP spreads to contiguous craniocervical segments (lower face, masticatory muscles, and neck). The term segmental craniocervical dystonia is applied to the combination of BSP and dystonia of other head and neck muscles (LeDoux, [2009](#mgg3411-bib-0046){ref-type="ref"}). Herein, BSP‐plus (BSP+) will be used to denote subjects with BSP who exhibit subsequent spread to other anatomical segments (LeDoux, [2009](#mgg3411-bib-0046){ref-type="ref"}; Waln & LeDoux, [2011](#mgg3411-bib-0093){ref-type="ref"}). Sensory tricks or geste antagonistes are highly specific to dystonia, reported in a high percentage of patients with BSP, and can facilitate the diagnosis of BSP (Defazio, Hallett, Jinnah, & Berardelli, [2013](#mgg3411-bib-0014){ref-type="ref"}). However, without valid genetic biomarkers, the diagnosis of BSP can be difficult, even for experienced clinicians (Defazio et al., [2013](#mgg3411-bib-0014){ref-type="ref"}).

Although rare cases of isolated BSP have been linked to *THAP1* (OMIM 609520) mutations (LeDoux et al., [2012](#mgg3411-bib-0050){ref-type="ref"}; Vemula et al., [2014](#mgg3411-bib-0091){ref-type="ref"}), the genetic underpinnings of this focal dystonia remain largely unknown. In one study, 233 relatives of 56 probands with primary BSP were examined and 27% had a first‐degree relative affected by BSP or other dystonia (Defazio, Martino, Aniello, Masi, Abbruzzese, et al., [2006](#mgg3411-bib-0017){ref-type="ref"}). Using an autosomal dominant model, penetrance was approximately 20% in pedigrees with BSP (Defazio, Martino, Aniello, Masi, Abbruzzese, et al., [2006](#mgg3411-bib-0017){ref-type="ref"}; Defazio, Martino, Aniello, Masi, Gigante, et al., [2006](#mgg3411-bib-0018){ref-type="ref"}). For comparison, penetrance of the classic ΔGAG mutation in *TOR1A* (OMIM 605204, DYT1) is 30%--40% (Bressman et al., [2000](#mgg3411-bib-0005){ref-type="ref"}). Approximately 10% of subjects in large biorepositories of isolated dystonia have a first‐ or second‐degree relative with dystonia (LeDoux et al., [2016](#mgg3411-bib-0049){ref-type="ref"}; Vemula et al., [2013](#mgg3411-bib-0090){ref-type="ref"}, [2014](#mgg3411-bib-0091){ref-type="ref"}; Xiao et al., [2010](#mgg3411-bib-0098){ref-type="ref"}, [2011](#mgg3411-bib-0099){ref-type="ref"}, [2012](#mgg3411-bib-0097){ref-type="ref"}). Even though late‐onset isolated dystonia has a considerable "heritable" component, large pedigrees adequately powered for linkage analysis are rare. Conversely, small multiplex pedigrees with 2 or 3 affected individuals are not uncommon.

In six published clinical series, 1st‐degree relatives of probands with isolated dystonia were subjected to examination (Defazio, Livrea, Guanti, Lepore, & Ferrari, [1993](#mgg3411-bib-0016){ref-type="ref"}; Defazio, Martino, Aniello, Masi, Abbruzzese, et al., [2006](#mgg3411-bib-0017){ref-type="ref"}; Leube, Kessler, Goecke, Auburger, & Benecke, [1997](#mgg3411-bib-0053){ref-type="ref"}; Stojanovic, Cvetkovic, & Kostic, [1995](#mgg3411-bib-0082){ref-type="ref"}; Waddy, Fletcher, Harding, & Marsden, [1991](#mgg3411-bib-0092){ref-type="ref"}). Within these reported families, overall phenotypic concordance‐discordance was approximately 50%--50%. However, discordant pedigrees are relatively more common in probands with BSP than cervical dystonia (Defazio, Berardelli, & Hallett, [2007](#mgg3411-bib-0013){ref-type="ref"}). An example of phenotypic discordance would be the presence of BSP in a proband and cervical dystonia in one of the proband\'s siblings. Phenotype concordance is the presence of a single anatomical distribution of dystonia (e.g., BSP) in all affected family members.

Herein, we report the results of whole‐exome sequencing (WES) of 31 subjects from 21 independent pedigrees with BSP and/or BSP+, the largest collection of BSP pedigrees examined to date. Our series includes both concordant and discordant pedigrees. Our results will facilitate a better understanding of the genetic underpinnings of isolated BSP and other, mainly adult‐onset, dystonias. A collection of *in silico* tools, including dbNSFP (Dong et al., [2015](#mgg3411-bib-0020){ref-type="ref"}; Liu, Jian, & Boerwinkle, [2011](#mgg3411-bib-0055){ref-type="ref"}; Liu, Wu, Li, & Boerwinkle, [2016](#mgg3411-bib-0056){ref-type="ref"}), dbscSNV (Jian, Boerwinkle, & Liu, [2014](#mgg3411-bib-0037){ref-type="ref"}), Combined Annotation‐Dependent Depletion (CADD; Kircher et al., [2014](#mgg3411-bib-0040){ref-type="ref"}), REVEL (Ioannidis et al., [2016](#mgg3411-bib-0036){ref-type="ref"}), and MutationTaster (Schwarz, Cooper, Schuelke, & Seelow, [2014](#mgg3411-bib-0075){ref-type="ref"}) were used to identify and prioritize candidate sequence variants. Putative disease‐associated variants were confirmed with bidirectional Sanger sequencing, followed by cosegregation analysis. Cosegregating deleterious variants in *CACNA1A* (OMIM 601011), *REEP4* (OMIM 609349)*, TOR2A* (OMIM 608052), *ATP2A3* (OMIM 601929), *HS1BP3* (OMIM 609359), *GNA14* (OMIM 604397) and *DNAH17* (OMIM 610063) were identified in single pedigrees.

2. MATERIALS AND METHODS {#mgg3411-sec-0006}
========================

2.1. Ethical compliance {#mgg3411-sec-0007}
-----------------------

All human studies were conducted in accordance with the Declaration of Helsinki with formal approval from the University of Tennessee Health Science Center Institutional Review Board (IRB; 01‐07346‐FB, 05‐08331‐XP, and 14‐03320‐XP) and ethics committees of all participating centers. All subjects gave written informed consent for genetic analyses and disclosure of medical information.

2.2. Subjects {#mgg3411-sec-0008}
-------------

Subjects in this study were examined by at least one neurologist with subspecialty expertise in movement disorders. Subjects were asked to perform specific tasks, including holding their eyes open, opening and closing their eyes gently, opening and closing their eyes forcefully, along with additional verbal and postural maneuvers designed to capture masticatory, laryngeal or cervical involvement. A clinical diagnosis of definite BSP was given to subjects that exhibited increased blinking and stereotyped, bilateral and synchronous orbicularis oculi spasms inducing narrowing/closure of the eyelids (Defazio et al., [2013](#mgg3411-bib-0014){ref-type="ref"}). Subjects with isolated episodes of increased eyelid blinking were given a diagnosis of possible BSP. Each affected or possibly affected family member was queried for the presence of sensory tricks. WES was completed on a total of 31 subjects from 21 pedigrees from the United States, Poland, and Italy (Table [1](#mgg3411-tbl-0001){ref-type="table"}). Prior to WES, pathogenic variants in *THAP1*,*GNAL* (OMIM 139312) and Exon 5 of *TOR1A* were excluded as previously described (LeDoux et al., [2012](#mgg3411-bib-0050){ref-type="ref"}; Vemula et al., [2013](#mgg3411-bib-0090){ref-type="ref"}; Xiao et al., [2009](#mgg3411-bib-0095){ref-type="ref"}, [2010](#mgg3411-bib-0098){ref-type="ref"}). Two pedigrees were African--American and 19 pedigrees were Caucasian of European descent. The results of WES on the proband of African--American pedigree 10908 were previously reported (Xiao, Thompson, Vemula, & LeDoux, [2016](#mgg3411-bib-0096){ref-type="ref"}) and deposited in Sequence Read Archive (SRX1790848).

###### 

BSP and BSP+ subjects examined with whole‐exome sequencing

  Subject        Age   Age of onset   Sex   Ethnicity   BSP family history   Anatomical distribution                                                   Select candidate genes
  -------------- ----- -------------- ----- ----------- -------------------- ------------------------------------------------------------------------- ----------------------------------------------------------------
  10012          77    60             F     Caucasian   No                   Segmental dystonia (BSP, oromandibular, lower face, cervical)             *KCNH4, CHRNA7, SPTBN4, ATP13A2*
  10014          70    47             F     Caucasian   No                   Segmental dystonia (BSP, oromandibular, lower face)                       *KCNG4, PLP1, KCNS1, ACLY, VPS13C*
  10035          67    55             F     Caucasian   No                   Segmental dystonia (BSP, oromandibular, lower face, cervical)             *TRPV4, TBP, IMP4, UBXN4*
  10036          69    66             F     Caucasian   No                   Segmental dystonia (BSP, cervical)                                        *HK1, PRUNE2, NUMBL, MRPL15*
  10043‐I‐1      83    57             M     Caucasian   Yes                  Segmental dystonia (BSP, oromandibular, lower face, cervical)             *GNA14, HS1BP3, NEFH, RWDD2A*
  10043‐II‐2     51    45             M     Caucasian   Yes                  Segmental dystonia (BSP, pharyngeal, laryngeal, cervical), Parkinsonism   *GNA14. HS1BP3, NEFH, RWDD2A*
  10064          60    47             M     Caucasian   Yes                  Segmental dystonia (BSP, oromandibular, lower face, cervical)             *HECW2, CDH4, RABL2B, AP4B1, SCN3A*
  10076          62    61             F     Caucasian   No                   Segmental dystonia (BSP, cervical)                                        *CAPN11, REEP2, MYO1B, DNAH17, ATP13A2*
  10178          59    20             M     Caucasian   Yes                  BSP                                                                       *ZZEF1, KCNA5, MUYOD1, MRPL15*
  10193          77    69             F     Caucasian   Yes                  BSP                                                                       *IGSF21, MYOD1*
  10274‐II‐3     56    45             M     AA          Yes                  Segmental dystonia (BSP, cervical)                                        *TRPV4, WDFY3, ZFYVE9*
  10274‐II‐6     50    50             F     AA          Yes                  BSP                                                                       *TRPV4, WDFY3, ZFYVE9*
  10455          58    48             F     Caucasian   Yes                  Segmental dystonia (BSP, oromandibular, lower face, cervical)             *CADPS, SNPH, ATP2B1, SLC12A2, CAPN11, VSP13DC, SPTBN4, BTNL3*
  10908‐II‐3     66    48             M     AA          Yes                  Segmental dystonia (BSP, oromandibular, lower face, cervical)             *REEP4*
  10908‐III‐9    33    30             M     AA          Yes                  BSP                                                                       *REEP4*
  25056          70    59             F     Caucasian   Yes                  Segmental dystonia (BSP, oromandibular, lower face, arm tremor)           *ABCA2, MYT1L*
  25069          61    56             M     Caucasian   Yes                  BSP (with arm tremor)                                                     *LRP1B, PCDHGA3, LAMA1, UNC13B, ATP13A2*
  25215          57    54             F     Caucasian   Yes                  BSP (with arm tremor)                                                     *AGAP1, EPS15L1, SCN1A, UNC13B, TOP3B*
  45263          78    77             M     Caucasian   Yes                  BSP                                                                       *INO80, DNAH17*
  85020          66    50             F     Caucasian   Yes                  BSP                                                                       *LRP1, GCH1, DDHD2, UNK*
  NG0362‐II‐2    57    39             M     Caucasian   Yes                  BSP                                                                       *CACNA1A*
  NG0362‐I‐1     76    67             M     Caucasian   Yes                  BSP                                                                       *CACNA1A*
  NG0362‐III‐1   35    NA             M     Caucasian   Yes                  BSP                                                                       *CACNA1A*
  NG0369‐II‐2    80    58             F     Caucasian   Yes                  BSP                                                                       *TOR2A, PCDH15, GTDC1*
  NG0369‐III‐2   52    NA             F     Caucasian   Yes                  BSP                                                                       *TOR2A, PCDH15, GTDC1*
  NG0369‐III‐6   46    NA             F     Caucasian   Yes                  BSP                                                                       *TOR2A, PCDH15, GTDC1*
  NG0450‐IV‐3    80    53             F     Caucasian   Yes                  BSP                                                                       *TRPV4, SERPINB9, CNTNAP2*
  NG0450‐V‐4     64    40             F     Caucasian   Yes                  BSP                                                                       *TRPV4, SERPINB9, CNTNAP2*
  NG0450‐V‐6     51    38             M     Caucasian   Yes                  Writer\'s cramp                                                           *TRPV4, SERPINB9, CNTNAP2*
  NG1072‐II‐5    72    NA             M     Caucasian   Yes                  BSP                                                                       *ATP2A3*
  NG1072‐IV‐2    24    21             F     Caucasian   Yes                  Cervical dystonia                                                         *ATP2A3*

AA, African--American; NA, not available.
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2.3. Whole‐exome sequencing {#mgg3411-sec-0009}
---------------------------

The concentration and quality of genomic DNA (gDNA) extracted from peripheral blood were examined with a NanoDrop^®^ ND‐1000 (Thermo Scientific), the Qubit^®^ dsDNA BR Assay Kit (Thermo Scientific) and agarose gel electrophoresis. DNA was then forwarded to Otogenetics or Beijing Genomics Institute (BGI) for additional in‐house quality control assessments prior to WES.

For WES at Otogenetics, 3 μg of genomic DNA (gDNA) was sheared to yield 100--450 bp fragments. In‐solution whole‐exome capture and massively parallel sequencing was performed using the Agilent SureSelect^XT^ All Exon Kit 51 Mb. Enriched DNA fragments were sequenced on Illumina\'s HiSeq 2500 platform as paired‐end 100--125 base‐pair reads. On average, over 95% of exons were covered at \>20×. The percentage of exome coverage was based on exons targeted by the 51 Mb All Exon v4 Kit which incorporates Consensus Coding Sequence (CCDS), NCBI Reference Sequence (RefSeq) and GENCODE annotations.

For WES at BGI, the gDNA samples were fragmented by Covaris, and, after two rounds of bead purification, the resulting gDNA fragments were mainly distributed between 200 and 400 bp. Then, AdA 5′‐ and 3′‐adaptors were ligated to the 5′‐ and 3′‐ends of the fragments, respectively. The AdA adaptor‐ligated fragments were amplified by PCR, and the PCR products were used for exon capture. A 58.95 Mb region was targeted for capture. The captured exon fragments were purified by DynabeadsM‐280 streptavidin bead purification and were further amplified by another round of PCR. Then, the PCR products were circularized and the resulting double strand (ds) circles digested with *Ecop15*. Among these digested fragments, small fragments were collected after bead purification. Similar to the AdA adaptor ligation, AdB adapters were ligated to both ends of the purified fragments and the fragments were then used for single strand (ss) circularization. The resulting ss circles were the final library products used on the CG Black Bird sequencing platform. Finally, high‐throughput sequencing was performed for each captured library.

2.4. Read mapping {#mgg3411-sec-0010}
-----------------

Sequence reads (FASTQ) from Illumina (Otogenetics) were mapped to the human reference genome (NCBI build 37.1) with NextGENe^®^ (SoftGenetics). Using the consolidation and elongation functions of NextGENe, instrument sequencing errors were reduced and sequence reads were lengthened prior to variant analysis. The condensation tool polished the data for adequate coverage by clustering similar reads with a unique anchor sequence. Using this process, short reads were lengthened and reads with errors were filtered or corrected. To maximize the probability of detecting causal variants, all base changes occurring in ≥4 reads in any individual sample were classified as variants for downstream analyses. An Overall Mutation score of 5 was used as a cut‐off to filter read errors and reduce the effects of allelic imbalances. The Overall Mutation score is generated via a proprietary algorithm (SoftGenetics) to provide an empirical estimation of the likelihood that a given variant call is genuine and not an artifact of sequencing or alignment errors. This score is based on the concept of Phred scores, where quality scores are logarithmically linked to error probabilities. With NextGENe^®^ software, intergenic and deep intronic (≥12 nt from splice sites) variants were eliminated prior to downstream *in silico* analyses.

Complete Genomics (BGI) developed high‐speed mapping software capable of aligning read data to reference sequences. Using GRCh37 as the reference, the mapping is tolerant of small variations from a reference sequence, such as those caused by individual genomic variation, read errors, or unread bases. To support assembly of larger variations, including large‐scale structural changes or regions of dense variation, each arm of a DNA Nanoball (DNB) is mapped separately, with mate pairing constraints applied after alignment. Initially, mapping reads to the human reference genome is a constrained process that does not allow for insertions and deletions. All mate‐pair constraint‐satisfying paired‐end mappings are used to detect small variants. DNBs are then filtered and individual reads are optimized. Optimization collects reads likely to lie in regions of interest, using mate alignment information and performs local *de novo* assemblies.

2.5. Single‐nucleotide variants (SNVs) and small insertions and deletions (INDELS) {#mgg3411-sec-0011}
----------------------------------------------------------------------------------

First, a list of shared variants was generated for pedigrees with two or more affected subjects analyzed with WES. For Otogenetics Illumina data, we eliminated SNVs and INDELS with minor allele frequencies (MAFs) ≥0.001 in the Exome Aggregation Consortium (ExAC; Lek et al., [2016](#mgg3411-bib-0051){ref-type="ref"}) database or 1000 Genomes (1KG), variants with unbalanced reads (variant allele \< 25%), and regions covered by \<5 reads. For BGI data, we eliminated SNVs and INDELs with MAFs ≥0.001 in 1 KG or Exome Variant Server (EVS). Of note, both BGI and Otogenetics outputs contain inverted major/minor allele classifications for a subset of sequence variants (minor allele: MAF \<0.001 or \>0.999). All nonsynonymous SNVs were analyzed with dbNSFP (versions 3.3 to 3.5; Liu et al., [2016](#mgg3411-bib-0056){ref-type="ref"}), CADD (Kircher et al., [2014](#mgg3411-bib-0040){ref-type="ref"}) and REVEL (Ioannidis et al., [2016](#mgg3411-bib-0036){ref-type="ref"}). Nonsynonymous SNVs with MetaLR (Dong et al., [2015](#mgg3411-bib-0020){ref-type="ref"}) ranking scores \>0.75, CADD phred scores \>15, or REVEL scores \>0.5 were retained for further evaluation. Nonsense SNVs, frameshift variants, synonymous SNVs, splice site SNVs, and other SNVs and INDELS (3′ and 5′ untranslated region \[UTR\] variants, downstream variants, intronic variants, noncoding variants and upstream variants) were analyzed with CADD +/− MutationTaster2 (Schwarz, Rodelsperger, Schuelke, & Seelow, [2010](#mgg3411-bib-0076){ref-type="ref"}). Nonsense SNVs, frameshift variants, synonymous SNVs, splice site SNVs, other SNVs and INDELs with CADD_phred scores \>15 were retained for further evaluation. All splice‐site SNVs were analyzed with dbscSNV1.1 (Jian et al., [2014](#mgg3411-bib-0037){ref-type="ref"}), which contains precomputed ensemble scores, Ada and RF, for all potential splice‐site SNVs computed using AdaBoost and random forests, respectively. Splice‐site SNVs with Ada scores \>0.6 or RF scores \>0.6 were retained for further evaluation. Particular attention was paid to variants within the DYT13 (1p36.32‐p36.13; Bentivoglio et al., [1997](#mgg3411-bib-0004){ref-type="ref"}; Valente et al., [2001](#mgg3411-bib-0089){ref-type="ref"}) and DYT21 (2q14.3‐q21.3) loci. The DYT13 locus was identified via linkage analysis of a large 3‐generation pedigree with craniocervical and other anatomical distributions of dystonia. Similarly, the DYT21 locus was defined through linkage analysis of a Swedish kindred with apparently autosomal dominant inheritance of dystonia which included BSP is several affected subjects (Forsgren, Holmgren, Almay, & Drugge, [1988](#mgg3411-bib-0027){ref-type="ref"}; Norgren, Mattson, Forsgren, & Holmberg, [2011](#mgg3411-bib-0063){ref-type="ref"}). Detailed methods for analysis of BGI and Otogenetics information can be found in the Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}.

REVEL, MetaLR and CADD scores were used to prioritize nonsynonymous missense variants for additional scrutiny whereas CADD and ExAC Probability of Loss‐of‐Function (LoF) intolerance (pLI) scores were used to prioritize nonsense SNVs and frameshift INDELs. MutationTaster was also used for analysis of small INDELs which are not scored by REVEL or MetaLR. Each category of variant (nonsynonymous, synonymous, splice‐site, nonsense, frameshift, other INDELs, and other SNVs) was ranked by *in silico* scores of deleteriousness. Population frequencies for the highest scoring variants were additionally assessed with genome Aggregation Database (gnomAD), NHLBI Exome Sequencing Project (ESP) Exome Variant Server (EVS) with particular attention to racial subcategories. All NCBI databases were queried with gene symbols and the names of encoded proteins. Particular attention was paid to data contained in PubMed, ClinVar, OMIM, and BioSystems. OMIM was searched for allelic disorders/phenotypes. MARRVEL and its link outs were used to explore available data related to animal models of homologs, genomic structural variants (DGV and DECIPHER), gene expression (GTex), and protein expression (ProteinAtlas). Gene expression was also analyzed with Allen Brain Atlas and BioGPS. Candidate genes were eliminated if not expressed in at least one "motor" region of the brain (striatum, cerebellum or frontal motor cortex). UniProt was used to access protein--protein interactions, sites of known or predicted posttranslational modifications and known or putative protein functions. Multiple sequence alignments were performed with Clustal Omega. A subset of candidate pathogenic variants was confirmed with bidirectional Sanger sequencing to exclude next generation sequencing read errors. After Sanger confirmation, cosegregation was assessed in individual pedigrees.

2.6. Copy number variant analysis {#mgg3411-sec-0012}
---------------------------------

CNVkit (Talevich, Shain, Botton, & Bastian, [2016](#mgg3411-bib-0085){ref-type="ref"}), a Python library and command‐line software toolkit to infer and visualize copy number variants (CNVs) from targeted DNA sequencing data, was used to detect CNVs in WES data generated by Otogenetics on the Illumina platform. CNVkit was designed for use on hybrid capture sequencing data where off‐target reads are present and can be used to improve copy number estimates. CNVkit normalizes read counts to a pooled reference and corrects for three main sources of bias: GC content, target footprint size, and repetitive sequences. For this purpose, Otogenetics provided us with WES data from 15 random subjects of unknown race and unknown geographic region of origin sequenced as part of unrelated projects using the Agilent SureSelect^XT^ All Exon Kit 51 Mb for exome capture and sequenced on Illumina\'s HiSeq 2500 platform.

CNVkit reports log2 copy ratios. Assuming pure samples and germline mutations, the log2 ratio should be −1.0 for a deletion mutation and infinity if both alleles are deleted. The log2 ratio is 0.585 for duplications and 1.0 for triplications. The relationship between the estimated copy number and the true copy number depends on a number of factors including read depth and number of probes covering a region of interest.

2.7. Sanger sequencing {#mgg3411-sec-0013}
----------------------

PCR was performed using 40 ng of peripheral blood gDNA along with 200 nmol/L of each primer (Table [S1](#mgg3411-sup-0002){ref-type="supplementary-material"}) in a 10‐μl reaction volume with HotStarTaq^®^ Plus DNA polymerase from Qiagen. The following cycling conditions were employed: 95°C for 15 min; 35 cycles at 95°C for 10 s, 58°C for 30 s, and 72°C for 30 s.

2.8. PCR validation of copy number variants {#mgg3411-sec-0014}
-------------------------------------------

Quantitative PCR (qPCR) was used for initial assessment of a random selection of predicted CNVs identified with CNVkit. Primers and probes for qPCR were designed with Roche\'s Universal Probe Library to cover (Table [S1](#mgg3411-sup-0002){ref-type="supplementary-material"}). qPCR was performed using 20 ng of template DNA and 200 nmol/L of each primer in a 10‐μl reaction volume with the LightCycler™ 480 system and Universal Taqman^®^ probes (Roche). The following cycling conditions were employed: 95°C for 5 min; 45 cycles at 95°C for 10 s, 58°C for 30 s, and 72°C for 12 s. Copy numbers were calculated against an endogenous control, *HLCS*, holocarboxylase synthetase. All assays were carried out in triplicate and means were used for calculating fold changes.

Digital PCR (dPCR) was then used for confirmation of select deletion and duplication CNVs identified with CNVkit. Literature mining as described for SNVs and small lNDELs was used to select genes with deletion log2 scores of −0.75 to −1.25 and covered by ≥4 probes, or genes with duplication log2 scores of 0.385 to 0.835 and covered by ≥4 probes. Primers and probes (FAM dye‐labeled) were designed via Roche\'s Universal Probe Library to encompass the estimated deletion regions (Table [S1](#mgg3411-sup-0002){ref-type="supplementary-material"}). The TaqMan copy number reference assay (Applied Biosystems 4403326) contained RNase P‐specific forward and reverse primers and VIC dye‐labeled TAMRA hydrolysis probe. RNase P, a single copy gene, is used as the reference for this work (Qin, Jones, & Ramakrishnan, [2008](#mgg3411-bib-0071){ref-type="ref"}).

Reaction mixtures (4.0 μl) containing TaqMan gene‐expression master mix (Life Technologies), 20X GE sample loading reagent (Fluidigm 85000746), 20X gene‐specific assays, 20X TaqMan copy number reference assay (Applied Biosystems) and 1.2 μl target gDNA (20 ng/μl) was pipetted into each loading inlet of a 48.770 dPCR array (Fluidigm). The BioMark IFC controller MX (Fluidigm) was used to uniformly partition the reaction from the loading inlet into the 770 × 0.84 nl chambers and dPCR was performed with the Fluidigm BioMark System for Genetic Analysis. The Fluidigm dPCR software was used to count gene copy numbers. The quality thresholds were manually set specific to each assay, but consistent across all panels of the same assay. The CNV calculation is based on "relative copy number" so that apparent differences in gene copy numbers in different samples are not distorted by differences in sample amounts. The relative copy number of a gene (per genome) is expressed as the ratio of the copy number of a target gene to the copy number of a single copy reference gene in the sample. By using assays for the two genes (the gene of interest and the reference gene) with two fluorescent dyes on the same Digital Array IFC, we are able to simultaneously quantitate both genes in the same DNA sample. The ratio of these two genes is the relative copy number of the gene of interest.

2.9. Data availability {#mgg3411-sec-0015}
----------------------

Primers (Table [S1](#mgg3411-sup-0002){ref-type="supplementary-material"}), WES variants examined with Sanger sequencing (Table [S2](#mgg3411-sup-0002){ref-type="supplementary-material"}), and potential CNVs examined with qPCR (Table [S3](#mgg3411-sup-0002){ref-type="supplementary-material"}) are included in Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}. Comprehensive WES variant analysis for each pedigree is included in individual Excel workbooks (10012, 10014, 10035, 10036, 10043, 10064, 10076, 10178, 10193, 10274, 10455, 10908, 25056, 25069, 25215, 45263, 85020, NB0362_BGI, NG0369, NG0450, and NG1072_BGI).

3. RESULTS {#mgg3411-sec-0016}
==========

3.1. BSP and BSP+ pedigrees {#mgg3411-sec-0017}
---------------------------

Whole‐exome sequencing was completed on 31 subjects from 21 distinct pedigrees with either concordant or discordant BSP and BSP+ phenotypes (Table [1](#mgg3411-tbl-0001){ref-type="table"}, Figures [1](#mgg3411-fig-0001){ref-type="fig"} and [2](#mgg3411-fig-0002){ref-type="fig"}, Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}). Exome coverage is provided in Tables [2](#mgg3411-tbl-0002){ref-type="table"} and [3](#mgg3411-tbl-0003){ref-type="table"}. Depth of coverage was ≥10× and ≥20× for over 97.5% and 95% of the 31 exomes. Numbers of total and filtered variants are provided in Table [4](#mgg3411-tbl-0004){ref-type="table"}.

![Blepharospasm (BSP) and BSP+ Pedigrees. Pedigrees with two or more affected individuals. Arrows, probands. Arrowheads, other family members analyzed with whole‐exome sequencing. White symbol, unaffected. Black symbols, BSP,BSP+ or other anatomical distribution of dystonia. Gray symbols, possibly affected](MGG3-6-601-g001){#mgg3411-fig-0001}

![Flow chart for whole‐exome sequencing data analysis. Analysis of exomes sequenced by Beijing Genomics Institute (BGI) and Otogenetics. Otogenetics (Illumina) reads were mapped in house. BGI did not provide raw read data](MGG3-6-601-g002){#mgg3411-fig-0002}

###### 

Exome coverage otogenetics (Illumina)

  Subjects       Exon coverage      Mapped reads       Reads in exons (% of mapped)                
  -------------- ------------------ ------------------ ------------------------------ ------------ ---------------------
  NG0369‐II‐2    182,985 (98.71%)   180,451 (97.20%)   158,686 (85.48%)               40,359,835   27,882,382 (69.08%)
  NG0369‐III‐2   183,285 (98.73%)   181,151 (97.58%)   164,561 (88.64%)               46,282,001   31,819,162 (68.75%)
  NG0369‐III‐6   183,245 (98.71%)   181,036 (97.52%)   163,455 (88.05%)               45,818,817   31,595,919 (68.95%)
  NG0450‐V‐4     183,339 (98.76%)   181,430 (97.73%)   167,149 (90.04%)               48,910,931   33,455,111 (68.41%)
  NG0450‐V‐6     183,262 (98.72%)   180,540 (97.25%)   160,781 (86.61%)               44,674,009   30,667,372 (68.64%)
  NG0450‐IV‐3    182,910 (98.53%)   180,235 (97.09%)   157,051 (84.60%)               38,518,463   26,893,126 (69.81%)
  10012          183,177 (98.67%)   179,968 (96.94%)   151,762 (81.75%)               43,360,914   30,295,318 (69.86%)
  10014          183,345 (98.76%)   180,745 (97.36%)   157,291 (84.73%)               45,133,245   30,866,426 (68.38%)
  10035          183,449 (98.82%)   181,074 (97.54%)   159,805 (86.08%)               47,593,537   32,451,839 (68.18%)
  10036          183,377 (98.78%)   180,492 (97.22%)   155,013 (83.50%)               43,455,430   29,831,744 (68.64%)
  10043‐II‐2     182,658 (98.39%)   179,067 (96.46%)   149,939 (80.77%)               36,183,050   23,982,731 (66.28%)
  10064          181,329 (97.67%)   174,416 (93.95%)   135,925 (73.22%)               31,906,497   23,887,178 (74.87%)
  10076          181,156 (97.58%)   175,038 (94.29%)   137,975 (74.32%)               30,495,728   22,423,886 (73.53%)
  10043‐I‐1      183,249 (98.71%)   181,131 (97.57%)   166,235 (89.54%)               50,010,351   34,444,302 (68.87%)
  10178          183,260 (98.72%)   180,253 (97.10%)   157,001 (84.57%)               44,071,238   29,754,633 (67.51%)
  10193          182,958 (98.55%)   179,944 (96.93%)   154,912 (83.44%)               40,787,072   27,819,791 (68.20%)
  10274‐II‐3     183,257 (98.72%)   180,866 (97.43%)   162,983 (87.79%)               44,609,530   29,931,870 (67.09%)
  10274‐II‐6     183,149 (98.66%)   181,247 (97.63%)   167,458 (90.2%)                54,207,882   36,192,334 (66.76%)
  10455          183,030 (98.59%)   180,044 (96.98%)   156,811 (84.47%)               48,944,558   30,884,770 (63.10%)
  10908‐II‐3     183,169 (98.67%)   181,017 (97.51%)   164,543 (88.63%)               47,084,143   32,159,148 (68.30%)
  10908‐III‐9    183,065 (98.6%)    183,065 (97.35%)   163,351 (87.99%)               45,541,395   30,924,196 (67.90%)
  25056          183,204 (98.68%)   180,273 (97.11%)   153,853 (82.87%)               45,212,675   30,858,562 (68.25%)
  25069          182,022 (98.05%)   176,604 (95.13%)   142,875 (76.96%)               33,328,570   24,217,999 (72.66%)
  25215          182,687 (98.41%)   179,180 (96.52%)   150,346 (80.99%)               37,771,677   25,469,621 (67.47%)
  45263          183,442 (98.81%)   181,182 (97.61%)   163,127 (87.87%)               48,922,580   33,055,765 (67.56%)
  85020          183,190 (98.68%)   180,786 (97.38%)   163,888 (88.28%)               58,478,165   35,599,118 (60.87%)

John Wiley & Sons, Ltd

###### 

Exome coverage BGI (Complete Genomics)

  Subject        Bases on targets   Targets covered ≥ 1×   Targets covered ≥ 5×   Targets covered ≥ 10×   Targets covered ≥ 20×
  -------------- ------------------ ---------------------- ---------------------- ----------------------- -----------------------
  NG0362‐III‐1   58,970,115         99.56%                 98.68%                 97.64%                  95.28%
  NG1072‐II‐5    58,970,115         99.57%                 98.72%                 97.70%                  95.36%
  NG0362‐II‐2    58,970,115         99.56%                 98.66%                 97.60%                  95.25%
  NG0362‐I‐1     58,970,115         99.59%                 98.76%                 97.73%                  95.32%
  NG1072‐IV‐2    58,863,950         99.54%                 98.66%                 97.62%                  95.27%

John Wiley & Sons, Ltd

###### 

Total and filtered variants

  Pedigree (\# subjects)   \# common variants (SNVs + INDELs)   Potentially pathogenic variants   Platform                             
  ------------------------ ------------------------------------ --------------------------------- ---------- ---- --- ---- ----- ----- -------------------
  NG0362 (3)               30,704                               68                                4          9    5   7    32    NA    Complete Genomics
  NG1072 (2)               31,417                               63                                1          8    4   5    42    NA    Complete Genomics
  NG0369 (3)               3,771                                60                                2          8    2   14   232   217   Illumina
  NG0450 (3)               3,749                                48                                3          8    0   13   214   145   Illumina
  10043 (2)                4,233                                82                                3          10   1   20   184   46    Illumina
  10274 (2)                5,462                                141                               6          10   2   25   26    110   Illumina
  10908 (2)                4,665                                79                                2          9    0   19   227   46    Illumina
  10012 (1)                6,511                                118                               3          9    1   6    243   60    Illumina
  10014 (1)                7,255                                173                               7          21   2   29   272   69    Illumina
  10035 (1)                7,016                                141                               7          16   4   23   251   38    Illumina
  10036 (1)                6,954                                137                               3          4    2   19   234   41    Illumina
  10064 (1)                14,196                               258                               5          36   9   30   347   50    Illumina
  10076 (1)                14,357                               178                               9          29   1   17   340   29    Illumina
  10178 (1)                7,865                                127                               8          21   2   33   239   14    Illumina
  10193 (1)                7,136                                129                               7          20   1   22   213   42    Illumina
  10455 (1)                7,551                                167                               7          24   1   25   262   80    Illumina
  25056 (1)                7,196                                170                               6          16   4   23   254   61    Illumina
  25069 (1)                9,064                                145                               4          22   3   23   254   11    Illumina
  25215 (1)                7,017                                176                               5          19   5   23   256   52    Illumina
  45263 (1)                9,340                                139                               2          19   3   25   277   25    Illumina
  85020 (1)                7,984                                151                               3          22   4   31   246   77    Illumina

SNVs, single nucleotide variants; INDELs, small deletion and insertions; CNVs, copy number variants; NA, not available.

SNVs and INDELs with (MAFs) \>0.001 (1 KG or EVS for Complete Genomics/BGI; and ExAC for Illumina/Otogenetics). Nonsynonymous SNVs: CADD phred score \>15 or MetaLR \>0.75 or REVEAL \>0.5. Nonsense SNVs: CADD phred score \>15. Synonymous SNVs: CADD phred score \>15. Splice‐site SNVs: CADD phred score \>15 or ada_score \>0.6 or rf_score \>0.6. Frame shift: CADD phred score \>15. Other SNVs & INDELs: CADD phred score \>15.

CNVs: all generated via analysis with CNVkit.

John Wiley & Sons, Ltd

3.2. *CACNA1A* INDEL in a three‐generation pedigree with BSP {#mgg3411-sec-0018}
------------------------------------------------------------

A novel *CACNA1A* INDEL (c.7261_7262delinsGT \[[NM_001127222.1](NM_001127222.1)\], p.Pro2421Val \[[NP_001120694.1](NP_001120694.1)\]) was identified in three males and one asymptomatic female family member from a three‐generation pedigree with BSP (Figure [3](#mgg3411-fig-0003){ref-type="fig"}, Tables [1](#mgg3411-tbl-0001){ref-type="table"}, [5](#mgg3411-tbl-0005){ref-type="table"}, 8 and [S2](#mgg3411-sup-0002){ref-type="supplementary-material"}; Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}). Complete Genomics outputted this variant as two contiguous SNVs. This INDEL is not reported in control databases (ExAC, 1KG or gnomAD) and predicted to be deleterious by CADD (Phred score = 19.51) and MutationTaster (disease causing, probability value: 1.0). However, two contiguous SNVs are reported in gnomAD (19:13318386 and 19:13318387) with very similar allele frequencies (211/118674 and 207/119456). Analysis of read data suggests that the majority of these SNVs are, in fact, part of the c.7261‐7262delinsGT INDEL. The 19:13318386G/A variant is present at relatively high frequency in the Finnish population (1.49E‐02) with a much lower allele frequency of (6.76E‐04) in non‐Finnish Europeans and quite rare in other racial populations. The identified amino acid substitution is located in the C‐terminal, intracellular domain of the encoded voltage‐dependent P/Q‐type calcium channel subunit α‐1A, which is conserved among mammals (Figure [3](#mgg3411-fig-0003){ref-type="fig"}). We did not screen other variants for cosegregation given previously established associations between *CACNA1A* and dystonia. Five SNVs had CADD_phred scores \>15 and REVEL scores \>0.5 but none had a MetaLR score \>0.75, REVEL score \>0.75 and CADD_phred score \>30. A frameshift INDEL in *MMP28* with a CADD_phred score of 34 is reported in ExAC and gnomAD. Four nonsense SNVs had CADD_phred scores \>30 but two are reported in ExAC and gnomAD and none seem biologically plausible candidates.

![*CACNA1A* INDEL Identified in a Multigenerational Pedigree with BSP. (a) Family NG0362 with BSP. Three affected (I‐1, II‐2 and III‐1) individuals were selected for WES. +/+, wild‐type; +/‐, heterozygous for *CACNA1A* c.7261_7262delinsGT. (b) Electropherograms of unaffected family member (II‐3) and subject with BSP (II‐2). (c) Multiple sequence alignment shows evolutionary conservation of Pro2421 among mammals. (d) Location of disease‐associated variants in the α‐1A subunit of P/Q type, voltage‐dependent, calcium channels: (1) Thr666Met variant linked to familial hemiplegic migraine and early‐onset cerebellar atrophy (Naik et al., [2011](#mgg3411-bib-0061){ref-type="ref"}; Ophoff et al., [1996](#mgg3411-bib-0064){ref-type="ref"}), (2) variant (c.3772delC) predicted to cause a frameshift and truncated protein or, more likely, nonsense‐mediated decay in a man with interictal BSP and episodic ataxia type 2 (Spacey et al., [2005](#mgg3411-bib-0081){ref-type="ref"}), (3), splice‐site variant associated with episodic ataxia type 2 (Ophoff et al., [1996](#mgg3411-bib-0064){ref-type="ref"}), (4) Ile1811Leu variant associated with familial hemiplegic migraine (Ophoff et al., [1996](#mgg3411-bib-0064){ref-type="ref"}), (5), Glu2080Lys variant linked to sporadic hemiplegic migraine (Thomsen et al., [2008](#mgg3411-bib-0087){ref-type="ref"}), (6), CAG expansion associated with spinocerebellar ataxia type 6 (SCA6) and dystonia (Kuo et al., [2017](#mgg3411-bib-0043){ref-type="ref"}; Sethi & Jankovic, [2002](#mgg3411-bib-0077){ref-type="ref"}; Zhuchenko et al., [1997](#mgg3411-bib-0100){ref-type="ref"}), (7) Pro2421Val variant associated with BSP in our multigenerational pedigree, (8), Pro2479Leu associated with sporadic hemiplegic migraine (Thomsen et al., [2008](#mgg3411-bib-0087){ref-type="ref"}), and (9) His2481Gln associated with sporadic hemiplegic migraine (Thomsen et al., [2008](#mgg3411-bib-0087){ref-type="ref"})](MGG3-6-601-g003){#mgg3411-fig-0003}

###### 

BSP‐associated sequence variants identified with whole‐exome sequencing, *in silico* analyses, and cosegregation analyses

  Pedigree   Phenotype   Gene        cDNA/Accession number                                    Protein              ExAC                   gnomAD                  dbSNP         MutationTaster2   CADD   MetaLR   REVEL
  ---------- ----------- ----------- -------------------------------------------------------- -------------------- ---------------------- ----------------------- ------------- ----------------- ------ -------- -------
  10908      BSP+/BSP    *REEP4*     c.109C\>T ([NM_025232.3](NM_025232.3))                   p.Arg37Trp           1.66E‐05 (2/120748)    2.03E‐05 (5/246118)     rs780399718   Disease causing   34.0   0.960    0.767
  NG0362     BSP         *CACNA1A*   c.7261_7262delinsGT ([NM_001127222.1](NM_001127222.1))   p.Pro2421Val         NA                     NA                      NA            Disease causing   19.5   NA       NA
  NG0369     BSP         *TOR2A*     c.568C\>T ([NM_130459.3](NM_130459.3))                   p.Arg190Cys          5.84E‐05 (7/119868)    4.07E‐05 (10/245852)    rs376074923   Disease causing   34.0   0.811    0.548
  NG1072     BSP         *ATP2A3*    c.1966C\>T ([NM_005173.3](NM_005173.3))                  p.Arg656Cys          5.51E‐04 (66/119706)   6.63E‐04 (183/276114)   rs140404080   Disease causing   34.0   0.992    0.872
  10043      BSP+        *GNA14*     c.989_990delCA ([NM_004297.3](NM_004297.3))              p.Thr330ArgfsTer67   1.65E‐05 (2/121284)    1.23E‐05 (3/244472)     NA            disease causing   36.0   NA       NA
  10043      BSP+        *HS1BP3*    c.94G\>T ([NM_022460.3](NM_022460.3))                    p.Gly32Cys           NA                     NA                      NA            Disease causing   34.0   0.803    0.454

NA, not available.

John Wiley & Sons, Ltd

3.3. *REEP4* missense variant {#mgg3411-sec-0019}
-----------------------------

A nonsynonymouse SNV in *REEP4* (c.109C\>T \[[NM_025232.3](NM_025232.3)\], p.Arg37Trp \[[NP_079508.2](NP_079508.2)\]) was identified in seven subjects with BSP+ or BSP and one asymptomatic female family member from a three‐generation African--American pedigree (Figure [4](#mgg3411-fig-0004){ref-type="fig"}, Tables [1](#mgg3411-tbl-0001){ref-type="table"}, [5](#mgg3411-tbl-0005){ref-type="table"}, 8 and [S2](#mgg3411-sup-0002){ref-type="supplementary-material"}; Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}). This variant is present at very low frequency in gnomAD and predicted to be deleterious by *in silico* analysis, including CADD (phred score = 34), REVEL (0.767), MetaLR (0.960), and MutationTaster2 (disease causing, probability value: 1.0). In gnomAD, this variant is not present in 15,290 African alleles. The p.Arg37Trp variant alters an amino acid that is highly conserved among vertebrates as shown by the multiple pairwise alignments generated with Clustal Omega (Figure [4](#mgg3411-fig-0004){ref-type="fig"}).

![*REEP4* Variant in African--American Pedigree with BSP+ and BSP. (a) Family 10908 with BSP+ and BSP. Two affected (II‐3 and III‐9) individuals were selected for WES. +/+, wild‐type; +/‐, heterozygous for *REEP4* c.109C\>T. (b) Electropherograms of unaffected family member (II‐2) and subject with BSP+ (II‐3). (c) Multiple sequence alignment shows evolutionary conservation of Arg37 among vertebrates](MGG3-6-601-g004){#mgg3411-fig-0004}

3.4. *TOR2A* missense variant {#mgg3411-sec-0020}
-----------------------------

A *TOR2A* nonsynonymous SNV (c.568C\>T \[[NM_130459.3](NM_130459.3)\], p.Arg190Cys \[[NP_569726.2](NP_569726.2)\]) was identified in three subjects with BSP and three asymptomatic members from a four generation pedigree (Figure [5](#mgg3411-fig-0005){ref-type="fig"}; Tables [1](#mgg3411-tbl-0001){ref-type="table"}, [5](#mgg3411-tbl-0005){ref-type="table"}, 8 and [S2](#mgg3411-sup-0002){ref-type="supplementary-material"}; Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}). This variant is present at low frequency in ExAC (5.84e‐05) and predicted to be deleterious by *in silico* analysis including CADD (phred score = 34), REVEL (0.548), MetaLR (0.811), and MutationTaster2 (disease causing, probability value: 1.0). The p.Arg190Cys variant alters an amino acid that is highly conserved among vertebrates as shown by the multiple pairwise alignments generated with Clustal Omega (Figure [5](#mgg3411-fig-0005){ref-type="fig"}). *TOR2A* encodes torsin family 2 member, a known interactor with dystonia‐associated protein torsinA (BioGRID). Nonsense variants in *PCDH15* and *GTDC1* were also detected in all three affected subjects and have CADD_phred scores \>30 but pLI scores of 0. *PCDH15* and *GTDC1* have 28 and 15 LoF variants in ExAC, respectively. *FRG1* variants detected with WES are likely due to mapping errors caused by related genomic sequences.

![*TOR2A* and *ATP2A3* Variants in Multigenerational Pedigrees with BSP. (a) Family NG0369 with BSP. Three affected (II‐2, III‐2 and III‐6) individuals were selected for WES. +/+, wild‐type; +/−, heterozygous for *TOR2A* c.568C\>T. (b) Electropherograms of unaffected family member (II‐6) and subject with BSP (II‐2). (c) Multiple sequence alignment shows evolutionary conservation of Arg190 among vertebrates. (d) Discordant pedigree NG1072 with BSP, cervical dystonia, and arm dystonia. Two affected individuals were selected for WES (II‐2, IV‐2). +/+, wild‐type; +/−, heterozygous for *ATP23* c.1966C\>T. White symbol, unaffected. Black symbol, BSP,BSP+ or other anatomical distribution of dystonia. Gray symbol, possibly affected. (e) Electropherograms of unaffected family member (II‐4) and subject with BSP (II‐2). (f) Multiple sequence alignment shows evolutionary conservation of Arg656 among vertebrates](MGG3-6-601-g005){#mgg3411-fig-0005}

3.5. *ATP2A3* missense variant {#mgg3411-sec-0021}
------------------------------

An *ATP2A3* nonsynonymous SNV (c.1966C\>T \[[NM_005173.3](NM_005173.3)\], p.Arg656Cys \[[NP_001120694.1](NP_001120694.1)\]) was identified in five affected subjects, one possibly affected subject, and three asymptomatic members of discordant Family NG1072 (Figure [5](#mgg3411-fig-0005){ref-type="fig"}; Tables [1](#mgg3411-tbl-0001){ref-type="table"}, [5](#mgg3411-tbl-0005){ref-type="table"}, 8 and [S2](#mgg3411-sup-0002){ref-type="supplementary-material"}; Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}). Predicted to be highly deleterious by all *in silico* analysis (CADD_phred score = 34, REVEL score = 0.872, MetaLR = 0.99175, MutationTaster2 \[disease causing, probability value: 1.0\]), this variant (rs140404080) is reported in ExAC (5.51E‐04) and gnomAD (6.63E‐04) with a population frequency of approximately 0.1%. The Arg656Cys variant alters an amino acid that is highly conserved among vertebrates (Figure [5](#mgg3411-fig-0005){ref-type="fig"}). Another candidate variant in *MYH13* (rs7807826) did not completely cosegregate with dystonia in this pedigree (Table [S2](#mgg3411-sup-0002){ref-type="supplementary-material"}, Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}). Moreover, expression of *MYH13* is mainly restricted to the extrinsic eye muscles. A nonsense variant in *NOS2* ([NM_000625.4](NM_000625.4): c.2059C\>T, p.Arg687\*; CADD_phred = 36) was shared by the two affected individuals analyzed with WES but *NOS2* is expressed at only low levels in brain and *Nos2* ^‐/‐^ mice have not been reported to manifest positive or negative motor signs. *ATP2A3* is highly expressed in cerebellar Purkinje cells (Allen Brain Atlas) and is a member of the P‐type ATPase superfamily that includes the gene (*ATP1A3*) causally associated with rapid‐onset dystonia‐Parkinsonism (DYT12).

3.6. *GNA14* and *HS1BP3* variants in pedigree with BSP+ and Parkinsonism {#mgg3411-sec-0022}
-------------------------------------------------------------------------

A novel *HS1BP3* nonsynonymous SNV (c.94C\>A \[[NM_022460.3](NM_022460.3)\], p.Gly32Cys \[[NP_071905.3](NP_071905.3)\]) was found in a father and son with severe BSP+ (Family 10043; Figure [6](#mgg3411-fig-0006){ref-type="fig"}; Tables [1](#mgg3411-tbl-0001){ref-type="table"}, [5](#mgg3411-tbl-0005){ref-type="table"}, 8 and [S2](#mgg3411-sup-0002){ref-type="supplementary-material"}; Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}). The deceased father had two brothers with clinical diagnoses of Parkinson disease (PD). The proband has BSP, mild lower facial dystonia, cervical dystonia and laryngeal respiratory dystonia. The laryngeal respiratory dystonia required treatment with a tracheostomy. The proband developed levodopa‐responsive Parkinsonism approximately 15 years after the onset of his dystonia. An ioflupane I‐123 dopamine transporter scan showed nigrostriatal denervation. The c.94C\>A \[[NM_022460.3](NM_022460.3)\] variant is not reported in ExAC, 1KG or gnomAD, and is predicted to be deleterious by all *in silico* analysis (CADD_phred score = 34, REVEL = 0.454, MetaLR = 0.803). Of note, a different variant in *HS1BP3* (p.A265G) was previously associated with essential tremor (ET), a disorder potentially related to the adult‐onset dystonias through common genetics (Higgins et al., [2005](#mgg3411-bib-0033){ref-type="ref"}). The p.Gly32Cys variant alters an amino acid that is highly conserved among vertebrates (Figure [6](#mgg3411-fig-0006){ref-type="fig"}).

![*GNA14* and *HS1BP3* Variants in Father and Son with BSP+. (a) Pedigree 10043. The proband has BSP+ and levodopa‐responsive Parkinsonism. His father had BSP+ and both were selected for WES. +/+, wild‐type; +/−, heterozygous for variants in *GNA14* and *HS1BP3*. (b) Electropherograms of unaffected family member (II‐1) and proband (II‐2) show *GNA14* variant. (c) Multiple sequence alignment shows evolutionary conservation of Thr330 among vertebrates. (d) Electropherograms of unaffected family member (II‐1) and proband (II‐2) show *HS1BP3* variant. (e) Multiple sequence alignment shows evolutionary conservation of Gly32 among vertebrates](MGG3-6-601-g006){#mgg3411-fig-0006}

A *GNA14* frameshift variant (c.989_990del \[[NM_004297.3](NM_004297.3)\], p.Thr330ArgfsTer67 \[[NP_004288.1](NP_004288.1)\]) was also identified in the same pedigree (Family 10043) and is present at low frequency in gnomAD (1.23E‐05) (Figure [6](#mgg3411-fig-0006){ref-type="fig"}; Tables [1](#mgg3411-tbl-0001){ref-type="table"}, [5](#mgg3411-tbl-0005){ref-type="table"}, and 8 and [S2](#mgg3411-sup-0002){ref-type="supplementary-material"}; Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}). This *GNA14* variant is predicted to be deleterious by CADD (phred score = 36) and MutationTaster2 (disease causing, probability value: 1.0). *GNA14* encodes G protein subunit α14 which shows modest expression in brain, particularly the striatum and cerebellum (Human Protein Atlas). Recently, somatic mutations in *GNA14* have been linked to congenital and sporadic vascular tumors (Lim et al., [2016](#mgg3411-bib-0054){ref-type="ref"}). Mutations in another G protein, Gα(olf), are associated with various anatomical distributions of mainly adult‐onset dystonia.

3.7. *DNAH17* variants found in pedigree and isolated subject with BSP {#mgg3411-sec-0023}
----------------------------------------------------------------------

Deleterious variants in *DNAH17* were identified in two brothers with BSP and one isolated case of BSP (Figure [7](#mgg3411-fig-0007){ref-type="fig"}; Tables [1](#mgg3411-tbl-0001){ref-type="table"}, [6](#mgg3411-tbl-0006){ref-type="table"}, 8 and [S2](#mgg3411-sup-0002){ref-type="supplementary-material"}, Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}). Both variants are present at low frequency in ExAC and gnomAD. *DNAH17* encodes dynein axonemal heavy chain 17. The FANTOM5 dataset reports expression of *DNAH17* in testes and brain (hippocampus, caudate and cerebellum; Kawaji, Kasukawa, Forrest, Carninci, & Hayashizaki, [2017](#mgg3411-bib-0038){ref-type="ref"}). *DNAH17* has not yet been linked to any other neurological or non‐neurological disease. A roundworm homolog (*dhc‐1*) of human *DNAH17* is involved in cytokinesis, microtubule‐based movement, mitotic spindle organization, meiotic nuclear division and nervous system development (MARRVEL).

![*DHAH17* Variants in Pedigree and Isolated Subject with BSP. (a) Pedigree 45263 with BSP. +/+, wild‐type; +/−, heterozygous for variant in *DNAH17*. (b) Electropherogram of proband (II‐2) showing *DNAH17* variant. (c) Multiple sequence alignment shows evolutionary conservation of Pro3158 among vertebrates. (d) Electropherogram of subject 10076 showing c.13295G\>A variant. (e) Multiple sequence alignment shows evolutionary conservation of Arg4432 among vertebrates](MGG3-6-601-g007){#mgg3411-fig-0007}

###### 

Candidate genes common to two or more pedigrees

  Gene       Pedigree   Variant (Accession Number)                                                    ExAC                   gnomAD                  dbSNP         MutationTaster2   CADD   MetaLR   REVEL
  ---------- ---------- ----------------------------------------------------------------------------- ---------------------- ----------------------- ------------- ----------------- ------ -------- -------
  *TRPV4*    10274      c.1337G\>T p.Arg446Leu ([NM_021625.4](NM_021625.4))                           2.64E‐04 (32/121218)   2.93E‐04 (81/276794)    rs143502097   Disease causing   34.0   0.943    0.845
  *TRPV4*    NG0450     c.745T\>A p.Tyr249Asn ([NM_001177431.1](NM_001177431.1))                      1.33E‐04 (16/120694)   1.01E‐04 (28/276982)    rs200210023   Disease causing   27.7   0.876    0.779
  *TRPV4*    10035      c.769C\>G p.Leu257Val ([NM_021625.4](NM_021625.4))                            8.04E‐04 (97/120672)   7.47E‐04 (207/276982)   rs56217500    Disease causing   23.8   0.958    0.669
  *CAPN11*   10076      c.425T\>C p.Leu142Pro ([NM_007058.3](NM_007058.3))                            NA                     3.23E‐05 (1/30926)      rs111320370   Disease causing   32     0.982    0.918
  *CAPN11*   10455      c.425T\>C p.Leu142Pro ([NM_007058.3](NM_007058.3))                            NA                     3.23E‐05 (1/30926)      rs111320370   Disease causing   32     0.982    0.918
  *DNAH17*   10076      c.13295G\>A p.Arg4432His ([NM_173628.3](NM_173628.3))                         6.60E‐05 (8/121400)    6.89E‐05 (19/275784)    rs775238626   Disease causing   35     0.763    0.477
  *DNAH17*   45263      c.9473C\>T p.Pro3158Leu ([NM_173628.3](NM_173628.3))                          9.93E‐05 (12/120872)   9.38E‐05 (26/277132)    rs371315860   Disease causing   25.3   0.947    0.613
  *VPS13C*   10014      c.10954C\>T p.Arg3652Ter ([NM_020821.2](NM_020821.2))                         1.84E‐04 (21/120740)   1.85E‐04 (50/270798)    rs138846118   Disease causing   49     NA       NA
  *VPS13C*   10455      c.9605C\>G p.Ala3202Gly ([NM_020821.2](NM_020821.2))                          8.45E‐06 (1/118378)    4.55E‐06 (1/219796)     rs750390167   Disease causing   33     0.869    0.598
  *UNC13B*   25069      c.4192A\>G p.Thr1398Ala ([NM_006377.3](NM_006377.3))                          NA                     NA                      NA            Disease causing   24     0.840    0.847
  *UNC13B*   25215      c.4754G\>A p.Arg1585His ([NM_006377.3](NM_006377.3))                          2.41E‐04 (29/120560)   2.56E‐04 (71/277062)    rs148652179   Disease causing   34     0.952    0.644
  *SPTBN4*   10012      c.1594G\>A p.Glu532Lys ([NM_020971.2](NM_020971.2))                           4.16E‐05 (5/120268)    6.16E‐05 (17/275852)    rs201278278   Disease causing   31     0.547    0.185
  *SPTBN4*   10455      c.1543C\>T p.Arg515Cys ([NM_020971.2](NM_020971.2))                           1.66E‐05 (2/120186)    4.48E‐05 (11/245642)    rs749869944   Disease causing   34     0.584    0.316
  *MYOD1*    10178      c.485C\>T p.Ala162Val ([NM_002478.4](NM_002478.4))                            2.97E‐04 (34/114390)   3.65E‐04 (95/260404)    rs150053079   Disease causing   23.1   0.977    0.678
  *MYOD1*    10193      c.485C\>T p.Ala162Val ([NM_002478.4](NM_002478.4))                            2.97E‐04 (34/114390)   3.65E‐04 (95/260404)    rs150053079   Disease causing   23.1   0.977    0.678
  *MRPL15*   10036      c.485_498delTAGCTATTGCTGCC p.Leu162HisfsTer109 ([NM_014175.3](NM_014175.3))   NA                     NA                      NA            Disease causing   35     NA       NA
  *MRPL15*   10178      c.201delT p.Fhe67LeufsTer30 ([NM_014175.3](NM_014175.3))                      3.05E‐04 (37/121336)   3.93E‐04 (109/277238)   NA            Disease causing   26.8   NA       NA

ExAC, Exome Aggregation Consortium; CADD, Combined Annotation Dependent Depletion; REVEL, Rare Exome Variant Ensemble Learner; NA, not available.
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3.8. Copy number variants {#mgg3411-sec-0024}
-------------------------

CNVkit called from 11 to 217 CNVs per shared exome. Assessing randomly selected CNVs with qPCR showed high discordancy (Table [S3](#mgg3411-sup-0002){ref-type="supplementary-material"}), particularly for variants that did not have log2 ratios near −1.0. We then focused on CNVs with log2 ratios compatible with a single‐copy gain (\~0.585) or single‐copy loss (−1.0) using dPCR. Deletions in *LILRA3* were confirmed in three unrelated subjects with BSP (Table [7](#mgg3411-tbl-0007){ref-type="table"}). *LILRA3* (OMIM 604818) deletions are common in the general population and may increase risk for HIV infection and some autoimmune disorders (Ahrenstorf et al., [2017](#mgg3411-bib-0001){ref-type="ref"}; Du et al., [2015](#mgg3411-bib-0022){ref-type="ref"}). A deletion in *BTNL3* (OMIM 606192) and duplications in *SLC2A14* (OMIM 611039), *SLC2A3* (OMIM 138170), *TOP3B* (OMIM 603582), and *UNK* (616375) were identified in single exomes (Tables [7](#mgg3411-tbl-0007){ref-type="table"} and [8](#mgg3411-tbl-0008){ref-type="table"}). *UNK* is expressed at high levels in brain (Allen Brain Atlas, BioGPS, and The Human Protein Atlas) and plays an important role in the development of neuronal morphology. Two *UNK* duplications are reported in ExAC. To date, UNK has not been linked to any medical disorder (OMIM). Copy number analysis of *GOLGA8A* (Chr15) was compromised by the presence of pseudogenes and a homolog with very close sequence similarity on Chr15.

###### 

Confirmation of CNV variants using Digital PCR of Genomic DNA

  Patient ID   Gene        hg19 CNV Coordinates         Log2Ratio   Digital PCR   
  ------------ ----------- ---------------------------- ----------- ------------- -------------
  10455        *BTNL3*     Chr5: 180416000--180429824   −0.95       0.50          Deletion
  10036        *LILRA3*    Chr19: 54801997--54804319    −1.13       0.62          Deletion
  10178        *LILRA3*    Chr19: 54801997--54804319    −0.91       0.55          Deletion
  10193        *LILRA3*    Chr19: 54801997--54804319    −1.04       0.60          Deletion
  25056        *SLC2A14*   Chr12: 7984292--8043706      0.53        1.52          Duplication
  25056        *SLC2A3*    Chr12: 8074017--8088678      0.53        1.51          Duplication
  25215        *TOP3B*     Chr22: 22312829--22330136    0.57        1.41          Duplication
  85020        *UNK*       Chr17: 73808156--73820465    0.58        1.50          Duplication
  25056        *CLEC18B*   Chr16: 74443499--74452124    −1.20       1.04          Normal
  10036        *CYP2A7*    Chr19: 41381608--41386459    −1.08       1.00          Normal
  10036        *LRRC49*    Chr15: 71229066--71305260    −0.92       1.05          Normal
  10036        *RRP7A*     Chr22: 42908850--42912408    −0.97       1.01          Normal
  25056        *GOLGA8A*   Chr15: 34673679--34681975    −0.93       1.45          Duplication
  45263        *GOLGA8A*   Chr15: 34677244--34681975    −0.94       1.08          Normal
  85020        *GOLGA8A*   Chr15: 34677244--34681975    −1.08       1.15          Normal

John Wiley & Sons, Ltd

###### 

Candidate gene literature mining

  Gene         Protein                                                              Function                                                                                                                                                                            ExAC pLI   ExAC Missense Z‐score   Diseases                                                                                      Neural localization[a](#mgg3411-note-0009){ref-type="fn"}
  ------------ -------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- ----------------------- --------------------------------------------------------------------------------------------- -------------------------------------------------------------
  *CACNA1A*    Calcium channel, voltage‐dependent, P/Q type, alpha 1A subunit       Calcium ion transmembrane transport                                                                                                                                                 1.00       7.23                    SCA6, EA‐2, hemiplegic migraine, dystonia                                                     High expression in cerebellum, especially in Purkinje cells
  *REEP4*      Receptor accessory protein 4                                         Microtubule‐binding, endoplasmic reticulum and nuclear envelope protein                                                                                                             0.18       0.20                    NA                                                                                            Purkinje cells, cerebellar nuclear neurons
  *TOR2A*      Torsin family 2, member A                                            ATP binding                                                                                                                                                                         0.06       0.04                    NA                                                                                            Moderate expression in brain
  *ATP2A3*     ATPase, Ca++ transporting, ubiquitous                                Calcium ion transport                                                                                                                                                               0.06       3.13                    NA                                                                                            High expression in cerebellum, especially in Purkinje cells
  *GNA14*      Guanine nucleotide‐ binding protein (G protein), alpha 14            Adenylate cyclase‐modulating G‐protein coupled receptor signaling pathway                                                                                                           0.00       −0.25                   NA                                                                                            Moderate expression in brain
  *HS1BP3*     HCLS1‐binding protein 3                                              Regulation of apoptotic process                                                                                                                                                     0.00       −0.24                   Associated with familial essential tremor                                                     Moderate expression in brain
  *NEFH*       Neurofilament protein, heavy polypeptide                             Axon development                                                                                                                                                                    0.00       0.88                    Charcot‐Marie‐Tooth disease Type 2CC, sporadic amyotrophic lateral sclerosis                  High expression in cerebellum, especially in Purkinje cells
  *RWDD2A*     RWD domain‐ containing 2A                                            NA                                                                                                                                                                                  0.00       0.64                    NA                                                                                            Moderate expression in brain
  *TRPV4*      Transient receptor potential cation channel, subfamily V, member 4   Actin cytoskeleton reorganization, calcium ion transmembrane transport                                                                                                              0.00       3.12                    Hereditary motor and sensory neuropathy, type IIc, brachyolmia type 3, metatropic dysplasia   Low expression in brain
  *SERPINB9*   Serpin family B member 9                                             Cellular response to estrogen stimulus                                                                                                                                              0.00       −0.70                   NA                                                                                            Moderate expression in brain
  *CNTNAP2*    Contactin associated protein‐like 2                                  Neuron projection development                                                                                                                                                       0.00       −0.91                   Cortical dysplasia‐focal epilepsy syndrome, Pitt--Hopkins like syndrome 1                     High expression in brain
  *CAPN11*     calpain 11                                                           Calcium‐dependent cysteine‐type endopeptidase activity                                                                                                                              0.00       −0.82                   NA                                                                                            Low expression in brain
  *DNAH17*     dynein, axonemal, heavy chain 17                                     Cilium‐dependent cell motility                                                                                                                                                      NA         NA                      NA                                                                                            Low expression in brain
  *VPS13C*     Vacuolar protein sorting 13 homolog C                                Negative regulation of parkin‐mediated stimulation of mitophagy in response to mitochondrial depolarization                                                                         0.00       −4.65                   Parkinson disease                                                                             Moderate expression in brain
  *UNC13B*     unc‐13 homolog B                                                     Neurotransmitter secretion                                                                                                                                                          0.00       0.51                    NA                                                                                            Moderate expression in brain
  *SPTBN4*     Spectrin, beta, nonerythrocytic 4                                    Axon guidance                                                                                                                                                                       NA         NA                      Myopathy, congenital, with neuropathy and deafness                                            High expression in brain
  *MYOD1*      Myogenic differentiation 1                                           Skeletal muscle fiber development                                                                                                                                                   0.00       1.96                    NA                                                                                            High expression in cerebellum
  *MRPL15*     Mitochondrial ribosomal protein L15                                  Mitochondrial translational elongation                                                                                                                                              0.00       0.52                    NA                                                                                            Moderate expression in brain
  *BTNL3*      Butyrophilin‐like protein 3                                          NA                                                                                                                                                                                  0.04       1.31                    NA                                                                                            Low expression in brain
  *TOP3B*      DNA topoisomerase 3‐beta‐1                                           Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex   0.11       3.18                    NA                                                                                            Moderate expression in brain
  *UNK*        RING finger protein unkempt homolog                                  Sequence‐specific RNA‐binding protein which plays an important role in the establishment and maintenance of the early morphology of cortical neurons during embryonic development   0.99       3.85                    NA                                                                                            Moderate expression in brain

ExAC, Exome Aggregation Consortium; CADD, Combined Annotation Dependent Depletion (v1.3); REVEL, Rare Exome Variant Ensemble Learner; NA, not available.

Based on Allen Brain Atlas, BioGPS and The Human Protein Atlas.
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3.9. Other candidate genes found in two or more pedigrees {#mgg3411-sec-0025}
---------------------------------------------------------

The strongest candidate variants (CADD_phred \>20 and MutationTaster2 = disease causing ± MetaLR \>0.75) were compared among all exomes from all pedigrees to identify common candidate genes. Three variants in *TRPV4* (OMIM 605427) were identified in three independent pedigrees. *TRPV4* has been associated with several medical disorders including autosomal dominant spinal muscular atrophy. However, all three variants are reported in ExAC and gnomAD at significant frequencies. The same SNV in *CAPN11* (OMIM 604822; [NM_007058.3](NM_007058.3): c.425T\>C, p.Leu142Pro) found in two independent pedigrees is reported once in gnomAD and has high CADD_phred (32), MetaLR (0.982) and REVEL (0.918) scores. *CAPN11* encodes calpain 11, an intracellular calcium‐dependent cysteine protease that shows highest expression in testis. One nonsense variant in *VPS13C* (OMIM 608879) was found in a single subject with BSP and a rare missense variant in *VPS13C* was found in another subject with BSP. Both of these *VPS13C* variants are predicted to be highly deleterious to protein function. Loss of VPS13C causes mitochondrial dysfunction and has been linked to autosomal recessive PD (Lesage et al., [2016](#mgg3411-bib-0052){ref-type="ref"}). Moreover, *VPS13C* variants may increase risk for PD, in general (Foo et al., [2017](#mgg3411-bib-0026){ref-type="ref"}), and, dystonia may share genetic underpinnings with PD (LeDoux et al., [2016](#mgg3411-bib-0049){ref-type="ref"}). Other candidate genes (*SPTBN4* \[OMIM 606214\], *MRPL15* \[OMIM 611828\], *UNC13B* \[605836\], and *MYOD1* \[159970\]) shared by two pedigrees show moderate‐to‐high expression in motor regions of brain. Mice carrying recessive loss‐of‐function *Sptbn4* mutations manifest ataxia, motor neuropathy, deafness and tremor (Parkinson et al., [2001](#mgg3411-bib-0068){ref-type="ref"}).

3.10. DYT13 and DYT21 loci {#mgg3411-sec-0026}
--------------------------

Within the DYT13 locus (Chr1), three subjects harbored *ATP13A2* (OMIM 610513) variants. Subject 10012 was found to have a missense variant (rs151117874, CADD_phred = 22.4, REVEL = 0.497, MetaLR = 0.8657, gnomAD = 21/272174 \[3.67E‐06\], Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}). Less deleterious synonymous (CADD_phred = 17.53) and missense (CADD_phred = 21.1) variants were found in subjects 10076 and 25069, respectively (Table [1](#mgg3411-tbl-0001){ref-type="table"}, Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}). Recessive mutations in *ATP13A2* have been linked to Kufor--Rakeb syndrome (Ramirez et al., [2006](#mgg3411-bib-0072){ref-type="ref"}) and spastic paraplegia 78 (Estrada‐Cuzcano et al., [2017](#mgg3411-bib-0024){ref-type="ref"}), both of which may include dystonia as a clinical manifestation. Variants in *ATP13A2* may also contribute to oligogenic inheritance in PD (Lubbe et al., [2016](#mgg3411-bib-0058){ref-type="ref"}). In subject 10035, a deleterious variant within the DYT21 (Chr2) locus was identified in *IMP4* (OMIM 612981; rs146322628, CADD_phred = 29.3, MetaLR = 0.83, REVEL = 0.606, gnomAD = 5.1E‐04, Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}), and deleterious variants in *UBR4* (OMIM 609890; rs748114415, CADD_phred = 23.3, REVEL = 0.188, MetaLR = 0.46, MutationTaster2 = 0.81 \[disease causing\], gnomAD = 5.1E‐04, Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}), and *ARHGEF19* (OMIM 612496; rs144638812, CADD_phred = 22.7, MetaLR = 0.64, REVEL = 0.11, MutationTaster2 = 0.55 \[disease causing\], gnomAD = 2.3E‐04, Data [S1](#mgg3411-sup-0001){ref-type="supplementary-material"}) were identified in the DYT13 (Chr1) locus. To date, *IMP4* and *ARHGEF19* have not been linked to a medical disorder. IMP4 interacts with the U3 snoRNA complex and is involved in nucleolar function (Granneman et al., [2003](#mgg3411-bib-0029){ref-type="ref"}). A missense variant in *UBR4* (p.Arg5091His) was found to segregate with episodic ataxia in a large Irish pedigree (Conroy et al., [2014](#mgg3411-bib-0009){ref-type="ref"}). UBR4 is expressed at high levels in cerebellar Purkinje cells (Allen Brain Atlas), interacts with calmodulin, colocalizes with ITPR1, and may be involved in Purkinje cell calcium homeostasis (Conroy et al., [2014](#mgg3411-bib-0009){ref-type="ref"}). *ARHGEF19* shows significant expression in cerebellar Purkinje cells (Allen Brain Atlas) and zebrafish *arhgef19* is involved in neural tube closure (Miles et al., [2017](#mgg3411-bib-0060){ref-type="ref"}).

4. DISCUSSION {#mgg3411-sec-0027}
=============

The molecular and cellular mechanisms underlying BSP and other anatomical distributions of isolated dystonia remain fragmentary. Accordingly, treatments for BSP are entirely symptomatic (Pirio Richardson et al., [2017](#mgg3411-bib-0069){ref-type="ref"}). Most commonly, BSP patients are treated with injections of botulinum toxin although, in some series, almost 50% report minimal improvement, no improvement or worsening of BSP after injections of botulinum toxins (Fernandez et al., [2014](#mgg3411-bib-0025){ref-type="ref"}). Identification of genetic etiologies for BSP may permit development of targeted disease‐modifying therapeutics. In this study, we used exome sequencing to explore genetic contributions to BSP and provide a foundation for future case--control studies of this important focal dystonia.

Although we do provide data suggesting potential roles for *CACNA1A, REEP4, TOR2A, ATP2A3, HS1BP3/GNA14*,*DNAH17*,*TRPV4*,*CAPN11*,*VPS13C*,*UNC13B*,*SPTBN4*,*MYOD1*, and *MRPL15* in the pathogenesis of BSP, the limitations of our work should be bordered. First, we did not identify a common cosegregating genetic etiology in more than one pedigree. This points to the likely genetic heterogeneity of BSP but also suggests that one or more variants identified herein cosegregated by chance alone. Unfortunately, none of our pedigrees were powered to generate LOD (logarithm \[base 10\] of odds) scores \>3 thereby precluding the usage of linkage analysis for validation of cosegregating variants. Second, several of the candidate variants identified with WES are reported in population databases (ExAC and gnomAD) with MAFs near the minimal population prevalence of BSP. On the other hand, noted MAFs are significantly lower than the maximal population prevalence of BSP with corrections for the markedly reduced penetrance characteristic of isolated dystonia. Furthermore, BSP and premonitory increased blinking may be much more common in the general population than commonly accepted (Conte et al., [2017](#mgg3411-bib-0010){ref-type="ref"}). Thirdly, our genetically heterogeneous cohort included Polish, Italian, Caucasian--American and African--American pedigrees, possibly reducing the probability of detecting variants shared among pedigrees and singletons. Accordingly, follow‐up case--control analysis of individual variants identified herein will require careful attention to population stratification and large sample sizes to confidently determine if variants in candidate genes are enriched in BSP. Fourth, our prioritization of variants was predominantly driven by *in silico* predictions of deleteriousness and many potentially pathogenic candidate variants were not confirmed with Sanger sequencing or subjected to cosegregation analysis. Fifth, WES will miss most repeat expansions and does not access the mitochondrial genome. In this regard, repeat expansions are a common cause of late‐onset neurological disease and mitochondrial mutations may include dystonia as part of a more expansive neurological phenotype (LeDoux, [2012](#mgg3411-bib-0048){ref-type="ref"}). Furthermore, our approach to CNV analysis was largely insensate to smaller structural variants such as single exonic deletions. Despite these limitations, our findings are compatible with common themes in dystonia research (calcium signaling, Purkinje cells, and dopaminergic signaling), point out potential genetic common ground with PD and ET, suggest a role for oligogenic inheritance in BSP, and provide motivation for treating a subset of BSP patients with acetazolamide.

*CACNA1A* is highly expressed in the cerebellum, particularly the Purkinje cell layer. Mutations in several genes related to calcium signaling and homeostasis and expressed in Purkinje cells have been causally associated with dystonia in humans and mice (LeDoux, [2011](#mgg3411-bib-0047){ref-type="ref"}). In fact, virtually all genes associated with dystonia in spontaneous mutants (*tottering*,*stargazer*,*ophisthotonus*,*ducky*,*lethargic*,*waddles*, and *wriggle*) are involved in Purkinje cell Ca^2+^ signaling (*Canca1a, Cacng2, Itpr1, Cacna2d2, Cacnb4*, and *Pmca2*). In humans, autosomal‐recessive mutations in *HPCA* (OMIM 142622) cause childhood‐onset dystonia and the encoded protein, hippocalcin, is robustly expressed in Purkinje cells and serves as a Ca^2+^ sensor (Charlesworth et al., [2015](#mgg3411-bib-0007){ref-type="ref"}; Tzingounis, Kobayashi, Takamatsu, & Nicoll, [2007](#mgg3411-bib-0088){ref-type="ref"}). SVs in *CACNA1A* have been associated with a variety of neurological disorders including episodic ataxia type 2, familial hemiplegic migraine, spinocerebellar ataxia type 6 (SCA6), and various anatomical distributions of dystonia such as benign paroxysmal torticollis of infancy and BSP (Naik, Pohl, Malik, Siddiqui, & Josifova, [2011](#mgg3411-bib-0061){ref-type="ref"}; Sethi & Jankovic, [2002](#mgg3411-bib-0077){ref-type="ref"}; Shin, Douglass, Milunsky, & Rosman, [2016](#mgg3411-bib-0079){ref-type="ref"}; Spacey, Materek, Szczygielski, & Bird, [2005](#mgg3411-bib-0081){ref-type="ref"}; Thomsen et al., [2008](#mgg3411-bib-0087){ref-type="ref"}). A notable percentage of patients with dystonia due to mutations in *CACNA1A* show significant improvement with acetazolamide (Spacey, [1993](#mgg3411-bib-0080){ref-type="ref"}; Spacey et al., [2005](#mgg3411-bib-0081){ref-type="ref"}). Unfortunately, our pedigree was lost to follow‐up and none of the affected family members were treated with acetazolamide. The α‐1 subunit of P/Q type, voltage‐dependent, calcium channel harbors a polyglutamine expansion in its C‐terminal intracellular domain and the novel missense variant p.Pro2421Val identified in our pedigree with BSP is near this expansion (Figure [3](#mgg3411-fig-0003){ref-type="fig"}). In contrast, the previously described BSP‐variant was likely associated with nonsense‐mediated decay and haploinsufficiency (Spacey et al., [2005](#mgg3411-bib-0081){ref-type="ref"}). Mutations linked to familial hemiplegic migraine appear to operate via gain‐of‐function mechanisms whereas the SCA6 polyglutamine repeat and loss‐of‐function mutations may lead to neuronal cell death (Cain & Snutch, [2011](#mgg3411-bib-0006){ref-type="ref"}). In this context, it is worthy to note that reduced Purkinje cell density was found in two individuals with BSP and cervical dystonia (Prudente et al., [2013](#mgg3411-bib-0070){ref-type="ref"}).

REEP4 is a microtubule‐binding endoplasmic reticulum and nuclear envelope protein (Schlaitz, Thompson, Wong, Yates, & Heald, [2013](#mgg3411-bib-0074){ref-type="ref"}). Depletion of REEP4 from HeLa cells is associated with defective cell division and proliferation of intranuclear membranes derived from the nuclear envelope (Schlaitz et al., [2013](#mgg3411-bib-0074){ref-type="ref"}). Similarly, omega‐shaped nuclear blebs have been used as a phenotypic measure of torsinA (encoded by *TOR1A*) dysfunction (Laudermilch et al., [2016](#mgg3411-bib-0044){ref-type="ref"}). In *Xenopus*, loss of REEP4 causes defects of nervous system development and paralysis of embryos (Argasinska et al., [2009](#mgg3411-bib-0003){ref-type="ref"}). Mutations in *REEP1* (OMIM 609139) and *REEP2* (OMIM 609347) are associated with spastic paraplegia (SPG) types 31 (SPG31), and 72 (SPG72). Although dystonia is not a clinical feature typically reported in SPG31 and SPG72 cases, dystonia is not uncommon in several other SPGs, including SPG7, SPG15, SPG26, SPG35, and SPG47 (van Gassen et al., [2012](#mgg3411-bib-0028){ref-type="ref"}; Klebe, Stevanin, & Depienne, [2015](#mgg3411-bib-0041){ref-type="ref"}).

A ΔGAG deletion in Exon 5 of *TOR1A* was the first SV to be linked to isolated dystonia (Ozelius et al., [1997](#mgg3411-bib-0066){ref-type="ref"}). TorsinA interacts with LAP1, a transmembrane protein ubiquitously expressed in the inner nuclear membrane. Recessive mutations of *TOR1AIP1* (OMIM 614512) which encodes LAP1 are associated with severe early‐onset generalized dystonia and progressive cerebellar atrophy (Dorboz et al., [2014](#mgg3411-bib-0021){ref-type="ref"}). Another torsinA interacting protein, torsin family 2 member A (encoded by *TOR2A*) was found to harbor a missense variant in one of our pedigrees with BSP. Similar to the ΔGAG mutation in *TOR1A*, the penetrance of the p.Arg190Cys missense variant identified in our pedigree was less than 50%. *TOR2A* is a member of the human torsin gene family (Laudermilch et al., [2016](#mgg3411-bib-0044){ref-type="ref"}; Ozelius et al., [1999](#mgg3411-bib-0067){ref-type="ref"}). *TOR1A*,*TOR2A* and *TOR1AIP1* all show relatively high expression in cerebellar Purkinje cells (Allen Brain Atlas).

A nonsynonymous SNV in *ATP2A3* ([NM_005173.3](NM_005173.3): c.1966C\>T, p.Arg656Cys) was found in five definitely‐affected subjects from a discordant pedigree with BSP from Italy. However, this variant was not detected in one possibly affected family member with writer\'s cramp. This could be either a phenocopy or evidence against the causality of *ATP2A3*. Furthermore, the p.Arg656Cys variant is present at notably high frequency in gnomAD (183/276,114 alleles, no homozygotes, 0.13% of 138,057 subjects). BSP is the most common focal dystonia in Italy with a crude prevalence rate of 133 per million or 0.013%. Even with a penetrance of \<20%, this suggests that p.Arg656Cys may not be pathogenic or, at least, pathogenic in isolation, requiring digenic inheritance of another pathogenic variant. On the other hand, p.Arg656Cys is predicted to be highly deleterious, may contribute to other anatomical distributions of dystonia, and, like *ATP1A3*, could be involved in the etiopathogenesis of other neurological disorders such as Parkinson disease, Alzheimer disease, and brain tumors (Kawalia et al., [2017](#mgg3411-bib-0039){ref-type="ref"}; Korosec, Glavac, Volavsek, & Ravnik‐Glavac, [2009](#mgg3411-bib-0042){ref-type="ref"}; Matak et al., [2016](#mgg3411-bib-0059){ref-type="ref"}). In this regard, *ATP2A3* shows striking expression in cerebellar Purkinje cells and dopaminergic neurons of the substantia nigra pars compacta (Allen Brain Atlas). *ATP2A3* encodes a sarcoplasmic/endoplasmic reticulum Ca^2+^ ATPase and disorders of Purkinje cell (LeDoux, [2011](#mgg3411-bib-0047){ref-type="ref"}) and dopaminergic (Surmeier, Halliday, & Simuni, [2017](#mgg3411-bib-0084){ref-type="ref"}) calcium homeostasis have been linked to dystonia and Parkinson disease, respectively.

A small pedigree (Figure [6](#mgg3411-fig-0006){ref-type="fig"}) with BSP+ and Parkinsonism harboring variants in *HS1BP3* and *GNA14* highlights the distinct possibility of oligogenic inheritance in BSP and other anatomical distributions of dystonia. In particular, all of the exomes sequenced in this study harbored more than one potentially pathogenic variant. Since most of our pedigrees were small and moderate numbers of variants showed *in silico* evidence of deleteriousness, we did not assess cosegregration for all of the identified candidate variants. However, we determined that both *GNA14* and *HS1PB3* were attractive candidate genes. Guanine nucleotide‐binding protein subunit alpha‐14 (encoded by *GNA14*) interacts with dynein, axonemal, light chain 4 (UniProt) which is expressed at high levels in sperm and brain. *GNA14* appears to play a key role in the genetic architecture underlying normal gray matter density (Chen et al., [2015](#mgg3411-bib-0008){ref-type="ref"}) and a *GNA14* deletion mutation has been reported in a patient with early‐onset Alzheimer disease (Lazarczyk et al., [2017](#mgg3411-bib-0045){ref-type="ref"}). *HS1BP3* shows moderate expression in brain (The Human Protein Atlas), and, in cerebellum, appears at highest levels in Purkinje cells (Allen Brain Atlas). Multipoint linkage analysis in four large pedigrees with ET identified a critical region between loci D2S2150 and D2S220 on Chr 2p which includes *HS1BP3* (Higgins, Loveless, Jankovic, & Patel, [1998](#mgg3411-bib-0034){ref-type="ref"}). The p.A265G HCLS1‐binding protein 3 (HS1BP3) variant encoded by *HS1BP3* is in linkage disequilibrium with ET but is unlikely to be causal since it is present at high frequency in the general population (Shatunov et al., [2005](#mgg3411-bib-0078){ref-type="ref"}). It remains unknown if other coding or noncoding variants in *HS1BP3* are causally related to the pathogenesis of ET. HS1BP3 negatively regulates auto‐phagy (Holland et al., [2016](#mgg3411-bib-0035){ref-type="ref"}), a cellular pathway closely tied to several neurodegenerative disorders including PD (Nash, Schmukler, Trudler, Pinkas‐Kramarski, & Frenkel, [2017](#mgg3411-bib-0062){ref-type="ref"}). In this regard, ET and PD may be related to adult‐onset dystonia through common genetics (De Rosa et al., [2016](#mgg3411-bib-0011){ref-type="ref"}; Dubinsky, Gray, & Koller, [1993](#mgg3411-bib-0023){ref-type="ref"}; Hedera et al., [2010](#mgg3411-bib-0032){ref-type="ref"}; LeDoux et al., [2016](#mgg3411-bib-0049){ref-type="ref"}; Louis et al., [2012](#mgg3411-bib-0057){ref-type="ref"}; Straniero et al., [2017](#mgg3411-bib-0083){ref-type="ref"}).

Oligenic inheritance is caused by mutations in two or more proteins with a functional relationship through direct interactions, membership in a pathway, or coexpression in a specific cell type. Given that functional groups of genes tend to colocalize within chromosomes (Thevenin, Ein‐Dor, Ozery‐Flato, & Shamir, [2014](#mgg3411-bib-0086){ref-type="ref"}), the possibility of oligogenic inheritance of variants found within a locus defined by linkage analysis cannot be ignored. Our focused analyses of the DYT13 and DYT21 loci provide genes and variants for cosegregation analysis in these previously detailed dystonia pedigrees and suggest that digenic or higher‐order oligogenic inheritance of variants within a disease‐associated locus may be causal in some pedigrees and isolated cases with BSP. In this context, cosegregating variants in *CIZ1* and *SETX* were linked to cervical dystonia in a large American pedigree (Xiao et al., [2012](#mgg3411-bib-0097){ref-type="ref"}).

Blepharospasm exerts important effects on health‐related quality of life (Hall et al., [2006](#mgg3411-bib-0030){ref-type="ref"}). Many patients with BSP experience annoying dry eye symptoms and photophobia (Hallett, Evinger, Jankovic, Stacy, & Workshop, [2008](#mgg3411-bib-0031){ref-type="ref"}). Oral medications such as anticholinergics and benzodiazepines are mildly beneficial in some subjects. Many patients with BSP show moderate benefit from injections of botulinum toxin. However, injections are expensive, painful and may be denied by third‐party payers. Although deep brain stimulation has been used to treat some individuals with BSP+ phenotypes, responses have been mixed (Reese et al., [2011](#mgg3411-bib-0073){ref-type="ref"}). Major advances in the treatment of BSP demand a deeper understanding of its genetic etiopathogenesis. Our work provides a platform for follow‐up case--control analyses of identified variants, evaluation of digenic and higher‐order oliogenic etiologies for BSP (Deltas, [2017](#mgg3411-bib-0019){ref-type="ref"}), and generation of animal models to help assess the pathogenicity of identified variants. Future work will demand attention to the effects of genetic background, oligogenic inheritance, pleiotropy, confounds of phenocopies, and the limitations of WES.
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